Charlotte Gatzweiler

Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models

Karen S. Frese, David C. Jones, F. Westermann, 2022, Cancers.

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

David T. W. Jones, Karen S. Frese, F. Westermann, 2021, Cancers.

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts

F. Westermann, O. Witt, B. Meder, 2020, Pharmaceuticals.

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

David C. Jones, M. Roussel, M. Kool, 2023, Journal of Neuro-Oncology.

The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.

David C. Jones, S. Pfister, W. Haefeli, 2022, Neuro-oncology.

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

David C. Jones, S. Pfister, K. Pajtler, 2022, Neuro-Oncology.